C80-A EVERYTHING YOU NEED TO KNOW ABOUT BRONCHOPULMONARY DYSPLASIA, CYSTIC FIBROSIS AND DIFFUSE PARENCHYMAL LUNG DISEASES: Pd-L1 In Pulmonary Lymphangioleiomyomatosis (lam): A Potential Therapeutic Target For Advanced Disease With Loss Of Tsc1/2

C80-A EVERYTHING YOU NEED TO KNOW ABOUT BRONCHOPULMONARY DYSPLASIA, CYSTIC FIBROSIS AND DIFFUSE PARENCHYMAL LUNG DISEASES: Pd-L1 In Pulmonary Lymphangioleiomyomatosis (lam): A Potential Therapeutic Target For Advanced Disease With Loss Of Tsc1/2

The discovery of the tumor suppressor tuberous sclerosis complex (TSC1/2) as a negative regulator of the mammalian target of rapamycin complex 1 (mTORC1) led to successful use of rapamycin in clinical trials and its FDA approval as the first treatment for LAM. [...]there remains an urgent need to id...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of respiratory and critical care medicine 2017-01, Vol.195
Hauptverfasser: Atochina-Vasserman, E N, Merrilees, M J, Lian, L, Rue, R, Zuo, N, Angel, L F, Abramova, E V, Gow, A, Kang, I, Wight, T N, ERuslanov, E B, Krymskaya, V P
Format: Artikel
Sprache:eng
Schlagworte:
Lung diseases
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The discovery of the tumor suppressor tuberous sclerosis complex (TSC1/2) as a negative regulator of the mammalian target of rapamycin complex 1 (mTORC1) led to successful use of rapamycin in clinical trials and its FDA approval as the first treatment for LAM. [...]there remains an urgent need to identify novel molecular targets for the treatment of LAM patients who have advanced disease or are unresponsive to the treatment with rapamycin.
ISSN:1073-449X
1535-4970